A polypeptide having 47 amino-acid residues which is obtained by enzymic degradation of urogastrone. The polypeptide obtained is a potent inhibitor of the secretion of acidic gastric juice and is of value in the treatment of duodenal ulcers.

A polypeptide having 46 amino-acid residues and obtained by enzymic degradation of urogastrone. The polypeptide is a potent inhibitor of the secretion of acidic gastric juice.

The present invention provides pharmaceutical preparations for anti-inflammation, anti-infection, inhibition of cancer metastasis etc., foods such as dairy products etc., and a method for improving proteins, as well as a method for diagnosis of inflammatory diseases and cancer malignancy. According to the present invention, there can be provided a polypeptide having poly-N-acetyllactosamine sugar chains synthesis-related activity, a process for producing the polypeptide, DNA coding for the polyp...

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one of various specified entities. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequ...

The modification of porcine or bovine insulin by treatment with a lysine specific amino-endopeptidase, which has the effect of removing L-lysyl-L-alanine from the B chain of the insulin. The products obtained have full insulin-like activity but are less antigenic.

The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.

The present invention provides pharmaceutical preparations for anti-inflammation, anti-infection, inhibition of cancer metastasis etc., foods such as dairy products etc., and a method for improving proteins, as well as a method for diagnosis of inflammatory diseases and cancer malignancy. According to the present invention, there can be provided a polypeptide having poly-N-acetyllactosamine sugar chains synthesis-related activity, a process for producing the polypeptide, DNA coding for the polyp...

The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.

Novel polypeptides of the formula wherein R.sub.1 is hydrogen, or a basic or neutral amino acid residue, R.sub.2 is a neutral amino acid residue and R.sub.3 is NH.sub.2, Tyr--NH.sub.2, a residue of tyrosyl peptides consisting of 1 to 5 amino acid residues or amides of the tyrosyl peptides, provided that when R.sub.1 is hydrogen, R.sub.2 is Pro, are effectively used for treatment of insufficiency of carbohydrate metabolism and of lipid metabolism, especially for the treatment of diabetes by not o...

Peptides of the formula: wherein: X is Trp or D-Trp, and Y is Pro-NHEt or the peptide segment --Gly--X.sub.1 --X.sub.2 --Arg--Pro--Z, wherein: X.sub.1 is Ala, D-Ala, or MeAla; X.sub.2 is Leu or D-Leu; and Z is --NH.sub.2 or --NHEt, Or the non-toxic pharmaceutically acceptable acid addition salts thereof, inhibit ovulation in warm-blooded animals.